Compare TNL & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNL | ALKS |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.5B |
| IPO Year | 2006 | 2012 |
| Metric | TNL | ALKS |
|---|---|---|
| Price | $62.96 | $34.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $84.00 | $43.43 |
| AVG Volume (30 Days) | 825.6K | ★ 2.3M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.22 | ★ 1.43 |
| Revenue | ★ $4,021,000,000.00 | $1,475,899,000.00 |
| Revenue This Year | $3.56 | $24.26 |
| Revenue Next Year | $3.55 | $4.47 |
| P/E Ratio | $52.95 | ★ $23.96 |
| Revenue Growth | ★ 4.06 | N/A |
| 52 Week Low | $43.81 | $25.17 |
| 52 Week High | $81.00 | $36.48 |
| Indicator | TNL | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 32.61 | 58.14 |
| Support Level | $57.94 | $27.48 |
| Resistance Level | $63.46 | $35.25 |
| Average True Range (ATR) | 2.87 | 0.94 |
| MACD | -1.45 | -0.11 |
| Stochastic Oscillator | 2.49 | 55.50 |
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including two vacation exchange brands, Vacation Ownership and Travel and Membership The majority of the revenue is earned from the United States.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.